
Beam Therapeutics Inc.
BEAMHealthcare|Biotechnology|US
$26.41
+0.54 (+2.09%)
Tangible Book / Share
$9.10
Cash / Share
$9.97
Next Earnings Report
Feb 23, 2027
EPS est. -$1.29 · Revenue est. $5.4M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.
Upcoming Data Readouts (8)
Dec 2026
Est. completion
Sickle Cell Trait
Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)
NCT06071377n=1,000
Dec 2026
Est. completion
P1P2Lymphoblastic Lymphoma
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
NCT05885464n=5
Dec 2027
Est. completion
P1P2Glycogen Storage Disease Type Ia
A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
NCT06735755n=36
Feb 2028
Est. completion
P1P2Sickle Cell Disease
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
NCT05456880n=15
May 2028
Est. completion
P1P2Alpha 1-Antitrypsin Deficiency
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
NCT06389877n=192
Sep 2028
Est. completion
NAGlioma
PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial
NCT06397560n=28
May 2029
Est. completion
P1T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
NCT06934382n=33
Feb 2043
Est. completion
Awaiting Results (3)
Trials past primary completion date but still active — data readout may be imminent.
Aug 2026
NA
Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Shenzhen)
NCT07153094Aug 2026
NA
Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei)
NCT07137195Aug 2026
NA
Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Sichuan)
NCT07152353Recent Press Releases
Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting
Nov 4, 2026 · GlobeNewsWire
Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio
Nov 3, 2026 · GlobeNewsWire
Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress
Oct 27, 2026 · GlobeNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
Oct 15, 2026 · PRNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
Oct 13, 2026 · GlobeNewsWire
Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress
Oct 13, 2026 · GlobeNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
Oct 8, 2026 · PRNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
Oct 6, 2026 · GlobeNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
Oct 1, 2026 · PRNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
Sep 29, 2026 · GlobeNewsWire
SEC Filings (61)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Nov 3, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Nov 3, 2026 | 8-K | Material event | DocumentIndex |
| Aug 14, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Aug 13, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Aug 4, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Aug 4, 2026 | 8-K | Material event | DocumentIndex |
| Jun 8, 2026 | 8-K | Material event | DocumentIndex |
| May 7, 2026 | 10-Q | Quarterly report | DocumentIndex |
| May 7, 2026 | 8-K | Material event | DocumentIndex |
| Apr 29, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Apr 17, 2026 | ARS | Annual report to holders | DocumentIndex |
| Apr 17, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 17, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Mar 26, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Mar 5, 2026 | 8-K | Material event | DocumentIndex |
| Feb 24, 2026 | S-8 | Employee stock plan | DocumentIndex |
| Feb 24, 2026 | 10-K | Annual report | DocumentIndex |
| Feb 24, 2026 | 8-K | Material event | DocumentIndex |
| Feb 12, 2026 | 8-K | Material event | DocumentIndex |
| Feb 9, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Feb 5, 2026 | 8-K | Material event | DocumentIndex |
| Feb 5, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Feb 5, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Feb 3, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Jan 12, 2026 | 8-K | Material event | DocumentIndex |
| Dec 11, 2025 | 8-K | Material event | DocumentIndex |
| Nov 5, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Nov 4, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Nov 4, 2025 | 8-K | Material event | DocumentIndex |
| Aug 7, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Aug 6, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Aug 5, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Aug 5, 2025 | 8-K | Material event | DocumentIndex |
| Jul 3, 2025 | 8-K | Material event | DocumentIndex |
| Jun 6, 2025 | 8-K | Material event | DocumentIndex |
| May 15, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| May 13, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| May 6, 2025 | 10-Q | Quarterly report | DocumentIndex |
| May 6, 2025 | 8-K | Material event | DocumentIndex |
| Apr 18, 2025 | ARS | Annual report to holders | DocumentIndex |